List of Zepzelca drug patents

Zepzelca is owned by Jazz.

Zepzelca contains Lurbinectedin.

Zepzelca has a total of 1 drug patent out of which 0 drug patents have expired.

Zepzelca was authorised for market use on 15 June, 2020.

Zepzelca is available in powder;intravenous dosage forms.

Zepzelca can be used as treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy..

Drug patent challenges can be filed against Zepzelca from 2024-06-15.

The generics of Zepzelca are possible to be released after 15 June, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7763615 JAZZ Ecteinascidin analogs for use as antitumour agents
Dec, 2024

(1 year, 8 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 15, 2025
Orphan Drug Exclusivity (ODE) Jun 15, 2027

Drugs and Companies using LURBINECTEDIN ingredient

NCE-1 date: 2024-06-15

Market Authorisation Date: 15 June, 2020

Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ZEPZELCA family patents

3

European Union

2

United Kingdom

2

Japan

1

Israel

1

Denmark

1

Austria

1

Mexico

1

Australia

1

Hong Kong

1

Slovenia

1

Russia

1

Hungary

1

Norway

1

Germany

1

United States

1

Portugal

1

Cyprus

1

Spain

1

Korea, Republic of

1

Poland

1

China

1

Canada

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in